{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T03:01:10Z","timestamp":1774494070700,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.vaccine.2016.12.053","type":"journal-article","created":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T16:17:19Z","timestamp":1484151439000},"page":"923-928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial"],"prefix":"10.1016","volume":"35","author":[{"given":"John J.","family":"Treanor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Essink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Muse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana M.","family":"El Sahly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruvim","family":"Izikson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen L.","family":"Goldenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Patriarca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"Dunkle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.12.053_b0005","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1056\/NEJMp068205","article-title":"H5N1 influenza \u2013 continuing evolution and spread","volume":"355","author":"Webster","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.12.053_b0010","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1086\/600035","article-title":"Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues","volume":"49","author":"Uyeki","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.053_b0015","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1126\/science.1222526","article-title":"The potential for respiratory droplet-transmissible A\/H5N1 influenza virus to evolve in a mammalian host","volume":"336","author":"Russell","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2016.12.053_b0020","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature10831","article-title":"Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA\/H1N1 virus in ferrets","volume":"486","author":"Imai","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2016.12.053_b0025","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S0264-410X(00)00395-9","article-title":"Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans","volume":"19","author":"Treanor","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.053_b0030","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1086\/590916","article-title":"Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A\/Vietnam\/1203\/04 H5N1 vaccine after priming with an antigenic variant","volume":"198","author":"Goji","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.053_b0035","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1016\/j.vaccine.2013.08.064","article-title":"Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5\/Indonesia\/05\/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant","volume":"31","author":"Treanor","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.053_b0040","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1128\/CVI.00368-08","article-title":"Qualification of the hemagglutination inhibition assay in support of pandmeic influenza vaccine licensure","volume":"16","author":"Noah","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2016.12.053_b0045","unstructured":"FDA. Guidance for Industry: Clinical data needed to support the licensure of pandemic influenza vaccines, vol. 2007, 2007."},{"key":"10.1016\/j.vaccine.2016.12.053_b0050","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2307\/3001616","article-title":"Some methods for strengthening the common chi-squared test","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"key":"10.1016\/j.vaccine.2016.12.053_b0055","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2307\/3001775","article-title":"Tests for linear trends in proportions and frequencies","volume":"11","author":"Armitage","year":"1955","journal-title":"Biometrics"},{"key":"10.1016\/j.vaccine.2016.12.053_b0060","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0149-2918(01)80044-8","article-title":"Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines","volume":"23","author":"Coats","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.vaccine.2016.12.053_b0065","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.12.053_b0070","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/infdis\/171.6.1595","article-title":"Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well-tolerated and induce protective immune responses in healthy adults","volume":"171","author":"Powers","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.053_b0075","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1086\/503050","article-title":"Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenzavirus hemagglutinin vaccine in elderly adults","volume":"193","author":"Treanor","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.053_b0080","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1001\/jama.297.14.1577","article-title":"Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial","volume":"297","author":"Treanor","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2016.12.053_b0085","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.vaccine.2009.10.037","article-title":"Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccines (TIV) among persons \u2a7e65 years old","volume":"28","author":"Keitel","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.053_b0090","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/j.vaccine.2011.01.039","article-title":"Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin vaccine administered intramuscularly to healthy adults 50\u201364 years of age","volume":"29","author":"Baxter","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.053_b0095","doi-asserted-by":"crossref","first-page":"7733","DOI":"10.1016\/j.vaccine.2011.07.128","article-title":"Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok) against influenza in healthy adults: a randomized, placebo-controlled trial","volume":"29","author":"Treanor","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.053_b0100","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa055778","article-title":"Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine","volume":"354","author":"Treanor","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.12.053_b0105","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0140-6736(07)61297-5","article-title":"Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial","volume":"370","author":"Leroux-Roels","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.12.053_b0110","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1086\/527489","article-title":"Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults","volume":"197","author":"Bernstein","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.053_b0115","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/jama.2014.12609","article-title":"Immunogenicity of avian influenza A\/Anhui\/01\/2005 (H5N1) vaccine with MF59 adjuvant: a randomized clinical trial","volume":"312","author":"Belshe","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2016.12.053_b0120","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/infdis\/jir328","article-title":"Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03A-adjuvanted vaccination in adults","volume":"204","author":"Lasko","year":"2011","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16312865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16312865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T11:52:22Z","timestamp":1568721142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16312865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0264410X16312865"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.12.053","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.12.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}